Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20972774 | 1.00 | CYP1A2 (0.35) | CYP1A2ALDH1A1CYP2C19TDP1AAK1 | |
| SCHEMBL20972779 | 0.86 | ALDH1A1 (0.42) | ALDH1A1PPARGLMNA | |
| SCHEMBL20972778 | 0.86 | ALDH1A1 (0.42) | ALDH1A1PPARGLMNA | |
| SCHEMBL20972780 | 0.84 | CYP1A2 (0.44) | CYP1A2ALDH1A1CYP2C19TDP1EGFR | |
| SCHEMBL20972782 | 0.84 | CYP1A2 (0.44) | CYP1A2ALDH1A1CYP2C19TDP1EGFR | |
| SCHEMBL22401206 | 0.82 | TDP1 (0.44) | ALDH1A1TDP1EGFR | |
| SCHEMBL22401207 | 0.82 | TDP1 (0.44) | ALDH1A1TDP1EGFR | |
| SCHEMBL22401208 | 0.78 | TDP1 (0.42) | CYP1A2ALDH1A1TDP1EGFR | |
| SCHEMBL28437449 | 0.78 | TDP1 (0.42) | CYP1A2ALDH1A1TDP1EGFR | |
| SCHEMBL22927463 | 0.76 | CYP1A2 (0.42) | CYP1A2ALDH1A1TDP1CNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275696-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2025-04-15 | — | — | US | disclosed |
| CN-111511357-B | Process for preparing tazicar | 德玛万科学有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230174445-A1 | PROCESS FOR PREPARING TAPINAROF | Dermavant Sciences GmbH (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20230174445-A1 | PROCESS FOR PREPARING TAPINAROF | Dermavant Sciences GmbH (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20230174445-A1 | PROCESS FOR PREPARING TAPINAROF | Dermavant Sciences GmbH (CH) | 2023-06-08 | — | — | US | disclosed |
| US-11597692-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2023-03-07 | — | — | US | disclosed |
| US-20210163388-A1 | PROCESS FOR PREPARING TAPINAROF | DERMAVENT SCIENCES GMBH (CH) | 2021-06-03 | — | — | US | disclosed |
| US-20210163388-A1 | PROCESS FOR PREPARING TAPINAROF | DERMAVENT SCIENCES GMBH (CH) | 2021-06-03 | — | — | US | disclosed |
| US-10961175-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2021-03-30 | — | — | US | disclosed |
| US-10961175-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2021-03-30 | — | — | US | disclosed |
| US-20210024442-A1 | PROCESS FOR PREPARING TAPINAROF | DERMAVENT SCIENCES GMBH (CH) | 2021-01-28 | — | — | US | disclosed |
| US-20210024442-A1 | PROCESS FOR PREPARING TAPINAROF | DERMAVENT SCIENCES GMBH (CH) | 2021-01-28 | — | — | US | disclosed |
| US-10647649-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2020-05-12 | — | — | US | disclosed |
| US-10647649-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2020-05-12 | — | — | US | disclosed |
| US-20190144367-A1 | PROCESS FOR PREPARING TAPINAROF | DERMAVENT SCIENCES GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
| US-20190144367-A1 | PROCESS FOR PREPARING TAPINAROF | DERMAVENT SCIENCES GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024442-A1 | PROCESS FOR PREPARING TAPINAROF | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-20210163388-A1 | PROCESS FOR PREPARING TAPINAROF | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-20230174445-A1 | PROCESS FOR PREPARING TAPINAROF | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-10961175-B2 | Process for preparing tapinarof | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-10647649-B2 | Process for preparing tapinarof | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-12275696-B2 | Process for preparing tapinarof | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-20190144367-A1 | PROCESS FOR PREPARING TAPINAROF | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
| US-11597692-B2 | Process for preparing tapinarof | TALDO1, TTR, CYP8B1 | CYP1A2 134/4885ALDH1A1 352/4885CYP2C19 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.